"Labetuzumab"

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles. End points were safety, response, pharmacokinetics

(CEACAM5) has recently been identified as an upregulated surface antigen in NEPC. We developed an immuno-PET agent targeting CEACAM5 and evaluated its ability to delineate AR prostate cancer in vivo. CEACAM5 expression was evaluated in a panel of prostate cancer cell lines by immunohistochemistry and Western blotting. The CEACAM5-targeting antibody labetuzumab was conjugated with the chelator desferrioxamine (DFO) and radiolabeled with Zr. The in vivo distribution of the radiolabeled antibody was evaluated in xenograft prostate cancer models by PET imaging and ex vivo organ distribution. The NEPC cell line H660 exhibited strong CEACAM5 expression, whereas expression was limited in the AR cell lines PC3 and DU145 and absent in the AR-positive cell line LNCaP. [Zr]Zr-DFO-labetuzumab imaging was able

) monoclonal antibody, labetuzumab, can be used as a tumor-targeting agent in colorectal cancer, since CEA is overexpressed in approximately 95% of colorectal cancer. Dual-labeled labetuzumab, labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (In), can be used as a tracer for dual-modality imaging. This study aimed to assess whether dual-modality imaging using In-diethylenetriaminepentaacetic acid (DTPA)-labetuzumab-IRDye800CW can detect pulmonary micrometastases in a mouse model. Pulmonary GW-39 human colonic carcinoma microcolonies were induced in athymic BALB/c mice by intravenous injection of 100 μL of a GW-39 cell suspension. After 1, 2, 3, and 4 wk of tumor growth, dual-modality imaging was performed 3 d after intravenous injection of In-DTPA-labetuzumab-IRDye800CW (10 μg, 25

Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly " patients (N = 24). Repeated RIT with I-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for "truly adjuvant" patients. However, the maximum safe dose of I-labetuzumab is a single administration of 50 millicuries/m . Cancer 2017;123:638-649. © 2016 American Cancer Society.

of tumors and radical excision of tumor tissue. Because humanized MN-14 (labetuzumab) is available for clinical use, translation to a clinical setting is the next step.

Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. We tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival. Resection of LM from colorectal cancer is the standard of care in this setting, yet two thirds will eventually relapse, and adjuvant systemic chemotherapy has failed to improve survival. Twenty-three patients who underwent R0 resection for LM of colorectal cancer received a dose of 40 to 60 mCi/m(2) (131)I-labetuzumab, a humanized monoclonal antibody against carcinoembryonic antigen. Safety (n = 23), disease-free survival, and overall survival (n

liver resection +/- preoperative 5-fluorouracil (5FU)-based chemotherapy (CTx). Postoperative strategy after R0-resection was either "wait and see" or "adjuvant" therapy (3 cycles of CTx or anti-carcinoembryonic antigen (CEA)-radioimmunotherapy with (131)I-labetuzumab in a dose of 40-50 mCi/m(2)). Forty-three initially unresectable patients received preoperative CTx for downsizing of their biCRC-LM

Carcinoma Colorectal Tumor Drug: hMN14 (labetuzumab) Phase 1 Phase 2 Study Design Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Study Type : Interventional (Clinical Trial Neoplasms Labetuzumab Intestinal Neoplasms Antineoplastic Agents, Immunological Gastrointestinal Neoplasms Antineoplastic Agents Digestive System Neoplasms To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds

More Information Brief Summary: The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.Condition or disease Intervention/treatment Phase Pancreatic Neoplasms Drug: hMN14 (labetuzumab) Phase 1 Phase 2 Study Design Go to Top of Page Study Description Study Design Arms and Interventions Outcome Pancreatic Tumor Additional relevant MeSH terms: Pancreatic Neoplasms Pancreatic Diseases Neoplasms Endocrine System Diseases Digestive System Neoplasms Labetuzumab Neoplasms by Site Antineoplastic Agents, Immunological Endocrine Gland Neoplasms Antineoplastic Agents Digestive

Neoplasms Colorectal Carcinoma Breast Cancer Breast Neoplasms Drug: hMN14 (labetuzumab) Phase 1 Phase 2 Study Design Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Study Type : Interventional (Clinical Trial Neoplasms by Histologic Type Rectal Diseases Neoplasms by Site Labetuzumab Breast Diseases Antineoplastic Agents, Immunological Skin Diseases Antineoplastic Agents To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds

Phase Colorectal Neoplasms Drug: hMN14 (labetuzumab) Phase 1 Study Design Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Study Type : Interventional (Clinical Trial Labetuzumab Neoplasms by Site Antineoplastic Agents, Immunological Digestive System Diseases Antineoplastic Agents To Top * For Patients and Families * For Researchers * For Study Record Managers * Home * RSS Feeds * Site Map * Terms and Conditions * Disclaimer * Customer Support * Copyright * Privacy * Accessibility * Viewers and Players

: IMMU 130This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.Other Names: * hMN14-SN38 * Labetuzumab-SN38 previously treated Additional relevant MeSH terms: Colorectal Neoplasms Irinotecan Intestinal Neoplasms Labetuzumab Gastrointestinal Neoplasms Immunoconjugates Digestive System Neoplasms Immunologic Factors Neoplasms by Site

* Labetuzumab-SN38 Criteria Contacts and Locations More Information Publications: Govindan SV, Goldenberg DM. New antibody conjugates in cancer therapy. ScientificWorldJournal. 2010 Oct 12;10:2070-89. doi: 10.1100/tsw.2010.191. Review. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin

BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005 Sep 20;23(27):6763-70. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R , Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007 Sep;14(9):2577-90. Epub 2007 Jun 15. Vorwerk H, Hermann RM, Christiansen H, Liersch T, Hess CF, Weiss E. A special device (double-hole belly board) and optimal

fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is expressed on > 95% of colorectal cancers.. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal cancer.Condition or disease Intervention/treatment Phase Peritoneal Carcinomatosis Colorectal Cancer Carcinoma Neoplasms Gastrointestinal Cancer Drug: Indium-111-DOTA-Labetuzumab-IRDye800CW injection Radiation: SPECT/CT scan Procedure: CRS extended with dual-modality imaging Phase 1 Phase 2 Detailed